Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein S29 pseudogene 22 (RPS29P22) is a genomic sequence in humans that is homologous to the protein-coding gene ribosomal protein S29 (RPS29), but lacks the ability to encode a functional protein due to disabling mutations[1][4][8]. Such pseudogenes typically arise via genomic duplication or retrotransposition events and serve as evolutionary remnants. The parent gene, RPS29, encodes a protein component of the 40S ribosomal subunit, essential for ribosome biogenesis and protein synthesis[3][5]. There is no evidence that RPS29P22 itself is translated or involved directly in any cellular function, nor is it considered a therapeutic target. Some pseudogenes have recently been suggested to exert regulatory effects on gene expression, but no such role is clearly established for RPS29P22[4][8].
None. No drugs target this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S29 pseudogene 22 (RPS29P22).